Zobrazeno 1 - 10
of 212
pro vyhledávání: '"GLP-1 RAs"'
Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
Autor:
Gisella Figlioli, Daniele Piovani, Spyros Peppas, Nicola Pugliese, Cesare Hassan, Alessandro Repici, Ana Lleo, Alessio Aghemo, Stefanos Bonovas
Publikováno v:
Pharmacological Research, Vol 210, Iss , Pp 107482- (2024)
Externí odkaz:
https://doaj.org/article/7044fe6d83b34f919693926ce0127e08
Autor:
Xuemin He, Siying Wen, Xixiang Tang, Zheyao Wen, Rui Zhang, Shasha Li, Rong Gao, Jin Wang, Yanhua Zhu, Dong Fang, Ting Li, Ruiping Peng, Zhaotian Zhang, Shiyi Wen, Li Zhou, Heying Ai, Yan Lu, Shaochong Zhang, Guojun Shi, Yanming Chen
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 6, Pp 2613-2630 (2024)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) protect against diabetic cardiovascular diseases and nephropathy. However, their activity in diabetic retinopathy (DR) remains unclear. Our retrospective cohort study involving 1626 T2DM patients
Externí odkaz:
https://doaj.org/article/fd1ba9ce290c4fe58910f5427a6731c9
Autor:
Laura Lungeanu-Juravle, Mirela Tache, Ana Radu, Carmen Dobjanschi, Petrisor Adamescu, Andra Nica, Emilia Rusu, Gabriela Radulian
Publikováno v:
Romanian Journal of Medical Practice, Vol 19, Iss 1, Pp 30-37 (2024)
Background. Heart failure with preserved ejection fraction is not a single disease but a clinical syndrome secondary to important comorbidities, is increasing in prevalence, and is associated with high functional impairment. This study aimed to compa
Externí odkaz:
https://doaj.org/article/de69e860b69f4edf88ca8e748d0ca032
Autor:
Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, Jenna Abu-Farha, Rayan Al-Harris, Aishwarya Mariam Ambi, Mohammed Altigani Abdalla, Fahd Al-Mulla, Mohamed Abu-Farha, Jehad Abubaker
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Obesity has become a global epidemic in the modern world, significantly impacting the global healthcare economy. Lifestyle interventions remain the primary approach to managing obesity, with medical therapy considered a secondary option, often used i
Externí odkaz:
https://doaj.org/article/f3be7a70f7a24022a72f7ee7f042c234
Autor:
Deqiang Zheng, Ning Li, Rui Hou, Xiaoyu Zhang, Lijuan Wu, Jan Sundquist, Kristina Sundquist, Jianguang Ji
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called for the investigation of GLP-1 RAs against diabetic retinopathy (DR), but the evidence is limited. By combini
Externí odkaz:
https://doaj.org/article/4ca1acef05554552a330629cd67d448e
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 14, Iss 1, Pp 1-12 (2022)
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been highly recommended for glycemic control and weight reduction. However, evidence has accumulated that GLP-1 RAs treatment is related to an increase in heart rate, whic
Externí odkaz:
https://doaj.org/article/0b1c321579b04e28b98988c15128c489
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Salvatore Greco, Vincenzo M. Monda, Giorgia Valpiani, Nicola Napoli, Carlo Crespini, Fabio Pieraccini, Anna Marra, Angelina Passaro
Publikováno v:
Biomedicines, Vol 11, Iss 8, p 2292 (2023)
Novel antidiabetic drugs have the ability to produce anti-inflammatory effects regardless of their glucose-lowering action. For this reason, these molecules (including GLP-1 RAs and DPP-4is) were hypothesized to be effective against COVID-19, which i
Externí odkaz:
https://doaj.org/article/5ec1da8d4c6b424dac92f12396adc5fd